Resovist® is an organ-specific
MRI contrast agent, used for the detection and characterization of especially small focal
liver lesions.
Resovist® consists of
superparamagnetic iron oxide (
SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the
liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the
signal intensity of normal
liver parenchyma on both T2- and
T1 weighted images.
Most malignant
liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved
contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous
bolus, which allows immediate imaging of the
liver and reduces the overall examination time. A dynamic imaging strategy after
bolus injection supports to characterize lesions.
In comprehensive clinical
trials, it demonstrated an excellent
safety profile.
In 2001, Resovist® was approved for the European market.
See also
Superparamagnetic Iron Oxide.
Resovist® competed with
Primovistâ„¢, the other
liver imaging agent of
Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.
•
] and 1 definition [
]
Further Reading:
Random Page
top
